Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 17, 2004, Pages 4569-4573

  Pullagurla, Manik R ^a   Westkaemper, Richard B ^a   Glennon, Richard A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Serotonin graphics models

Indexed keywords

RECEPTOR BLOCKING AGENT; SEROTONIN RECEPTOR;

ARTICLE; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

HUMANS; PROTEIN BINDING; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 3843107087     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.076     Document Type: Article

References (23)

1. Hoyer D., Hannon J.P., Martin G.R. Pharmacol. Biochem. Behav. 71:2002;533-554
2. A new nomenclature for 5-HT receptors Humphrey P.P.A., Hartig P.R., Hoyer D. Trends Pharmacol. Sci. 14:1993;233-236
3. Kroeze W.K., Kristiansen K., Roth B.L. Curr. Top. Med. Chem. 2:2002;507-528
4. Slassi A., Isaac M., O'Brien A. Expert Opin. Ther. Patents. 12:2002;513-527
5. Glennon R.A. J. Med. Chem. 46:2003;2795-2812
6. Woolley M.L., Marsden C.A., Fone K.C.F. Curr. Drug Top. 3:2004;59-79
7. Glennon R.A., Bondarev M., Roth B.L. Med. Chem. Res. 9:1999;108-117
8. Tsai Y., Dukat M., Slassi A., MacLean N., Demchyshyn L., Savage J.E., Roth B.L., Hufesein S., Lee M., Glennon R.A. Bioorg. Med. Chem. Lett. 10:2000;2295-2299
9. Glennon R.A., Lee M., Rangisetty J.B., Dukat M., Roth B.L., Savage J.E., McBride A., Rauser L., Hufesien L., Lee D.K.H. J. Med. Chem. 43:2000;1011-1018
10. Lee M., Rangisetty J.B., Dukat M., Slassi A., MacLean N., Lee D.K.H., Glennon R.A. Med. Chem. Res. 10:2000;230-242
11. Pullagurla M., Setola V., Roth B.L., Glennon R.A. Bioorg. Med. Chem. Lett. 13:2003;3355-3359
12. Westkaemper R.B., Glennon R.A. Curr. Top. Med. Chem. 2:2002;575-598
13. Bower M.J., Cohen F.E., Dunbrack R.L. J. Mol. Biol. 267:1997;1268-1282
14. Boess F.G., Monsma F.J. Jr., Meyer V., Zwingelstein C., Sleight A.J. Mol. Pharmacol. 52:1997;515-523
15. Boess F.G., Monsma F.J. Jr., Sleight A.J. J. Neurochem. 71:1998;2169-2177
16. Boess F.G., Monsma F.J. Jr., Bourson A., Zwingelstein C., Sleight A.J. Ann. N.Y. Acad. Sci. 861:1998;242-243
17. Bromidge, S. M. In Special Publication - Roy. Soc. Chem. 2001; Vol. 264, pp 101-119
18. Pullagurla, M. R. Doctoral Dissertation, Virginia Commonwealth University, December, 2003
19. Hirst W.D., Abrahamsen B., Blaney F.E., Calver A.R., Aloj L., Price G.W., Medhurst A.D. Mol. Pharmacol. 64:2003;1295-1308
20. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., Meltzer H.Y., Sibley D.R., Roth B.L., Hamblin M.W. J. Neurochem. 66:1996;47-56
21. Baldwin J.M., Schertler G.F., Unger V.M. J. Mol. Bio. 272:1997;144-164
22. Biotech Validation Suite for Protein Structures, http//biotech. emblheidelberg.de
23. 303 carboxylate group